» Articles » PMID: 11884610

Reversal of Growth Suppression by P107 Via Direct Phosphorylation by Cyclin D1/cyclin-dependent Kinase 4

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2002 Mar 9
PMID 11884610
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

p107 functions to control cell division and development through interaction with members of the E2F family of transcription factors. p107 is phosphorylated in a cell cycle-regulated manner, and its phosphorylation leads to its release from E2F. Although it is known that p107 physically associates with E- and A-type cyclin/cyclin-dependent kinase 2 (Cdk2) complexes through a cyclin-binding RXL motif located in the spacer domain, the mechanisms underlying p107 inactivation via phosphorylation remain poorly defined. Recent genetic evidence indicates a requirement for cyclin D1/Cdk4 complexes in p107 inactivation. In this work, we provide direct biochemical evidence for the involvement of cyclin D1/Cdk4 in the inactivation of p107's growth-suppressive function. While coexpression of cyclin D1/Cdk4 can reverse the cell cycle arrest properties of p107 in Saos-2 cells, we find that p107 in which the Lys-Arg-Arg-Leu sequence of the RXL motif is replaced by four alanine residues is largely refractory to inactivation by cyclin D/Cdk4, indicating a role for this motif in p107 inactivation without a requirement for its tight interaction with cyclin D1/Cdk4. We identified four phosphorylation sites in p107 (Thr-369, Ser-640, Ser-964, and Ser-975) that are efficiently phosphorylated by Cdk4 but not by Cdk2 in vitro and are also phosphorylated in tissue culture cells. Growth suppression by p107 containing nonphosphorylatable residues in these four sites is not reversed by coexpression of cyclin D1/Cdk4. In model p107 spacer region peptides, phosphorylation of S640 by cyclin D1/Cdk4 is strictly dependent upon an intact RXL motif, but phosphorylation of this site in the absence of an RXL motif can be partially restored by replacement of S643 by arginine. This suggests that one role for the RXL motif is to facilitate phosphorylation of nonconsensus Cdk substrates. Taken together, these data indicate that p107 is inactivated by cyclin D1/Cdk4 via direct phosphorylation and that the RXL motif of p107 plays a role in its inactivation by Cdk4 in the absence of stable binding.

Citing Articles

Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth.

Hawsawi O, Xue W, Du T, Guo M, Yu X, Zhang M Cell Rep Med. 2025; 6(1):101890.

PMID: 39793570 PMC: 11866447. DOI: 10.1016/j.xcrm.2024.101890.


Modeling breast cancer proliferation, drug synergies, and alternating therapies.

He W, Demas D, Shajahan-Haq A, Baumann W iScience. 2023; 26(5):106714.

PMID: 37234088 PMC: 10206440. DOI: 10.1016/j.isci.2023.106714.


Mathematically Modeling the Effect of Endocrine and Cdk4/6 Inhibitor Therapies on Breast Cancer Cells.

He W, Shajahan-Haq A, Baumann W Methods Mol Biol. 2023; 2634():337-355.

PMID: 37074587 DOI: 10.1007/978-1-0716-3008-2_16.


A Mechanistic Model for Cell Cycle Control in Which CDKs Act as Switches of Disordered Protein Phase Separation.

Krasinska L, Fisher D Cells. 2022; 11(14).

PMID: 35883632 PMC: 9321858. DOI: 10.3390/cells11142189.


Retinoblastoma Protein Paralogs and Tumor Suppression.

Flores M, Goodrich D Front Genet. 2022; 13:818719.

PMID: 35368709 PMC: 8971665. DOI: 10.3389/fgene.2022.818719.


References
1.
Holmes J, Solomon M . A predictive scale for evaluating cyclin-dependent kinase substrates. A comparison of p34cdc2 and p33cdk2. J Biol Chem. 1996; 271(41):25240-6. DOI: 10.1074/jbc.271.41.25240. View

2.
Bruce J, Hurford Jr R, Classon M, Koh J, Dyson N . Requirements for cell cycle arrest by p16INK4a. Mol Cell. 2000; 6(3):737-42. DOI: 10.1016/s1097-2765(00)00072-1. View

3.
Zhu L, Enders G, Lees J, Beijersbergen R, Bernards R, Harlow E . The pRB-related protein p107 contains two growth suppression domains: independent interactions with E2F and cyclin/cdk complexes. EMBO J. 1995; 14(9):1904-13. PMC: 398289. DOI: 10.1002/j.1460-2075.1995.tb07182.x. View

4.
Sherr C, Roberts J . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13(12):1501-12. DOI: 10.1101/gad.13.12.1501. View

5.
Harbour J, Dean D . The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000; 14(19):2393-409. DOI: 10.1101/gad.813200. View